Date: 2014-05-14
Type of information: Licensing agreement
Compound: CSL334 (anti-IL13 receptor monoclonal antibody)
Company: CSL (Australia) ASLAN Pharmaceuticals (Singapore)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: licensing
Action mechanism: CSL334 is a fully human monoclonal antibody against interleukin-13 receptor ?1 that has been shown to block binding and signal transduction of both IL4 and IL13. CSL334 is currently in preclinical development.
Disease: asthma
Details: * On May 14, 2014, Aslan Pharmaceuticals announced a global license agreement to develop CSL\'s anti-IL13 receptor monoclonal antibody, CSL334, currently in preclinical development for the treatment of asthma. Under the agreement, Aslan will fund and develop CSL334 through to clinical proof of concept in a development program conducted primarily in Asia, targeting patients suffering moderate persistent to severe allergic asthma whose disease is not adequately controlled by existing treatments. Upon achievement of clinical proof of concept, Aslan will identify a global partner for phase 3 development and commercialisation.
Financial terms: CSL will be entitled to share returns generated by Aslan from partnering the project. Further financial details were not disclosed
Latest news:
